ÂÜÀòÂÒÂ×

Janet Horton is an Executive Director, Clinical Development, at Aktis Oncology. Janet joined Aktis from G1 Therapeutics, Inc. where she was a contributor to the 2021 approval of COSELATM (trilaciclib) in small cell lung cancer. Janet held roles of increasing clinical development responsibility at G1 as the lead physician for numerous trilaciclib studies across Phases I-IV and as a provider of medical input for life cycle management. Prior to joining G1, Janet spent 12 years in academic medicine as a board-certified radiation oncologist specializing in the treatment of patients with breast cancer. During that time, she was an invited lecturer and had an active clinical and translational research program focused on developing a radiotherapy approach that could be tailored to tumor biology. She was the principal investigator on several early-phase clinical trials and an author on more than 50 radiation-related publications. Janet practiced first at Wake Forest University and subsequently at Duke University where she retains an appointment as an Adjunct Associate Professor of Radiation Oncology.

Janet earned her MD from Wake Forest University and completed her residency training in radiation oncology at the University of North Carolina at Chapel Hill. As part of the team at Aktis, Janet hopes to leverage her radiation oncology and clinical development experience to help bring targeted radiopharmaceuticals to as many patients as possible. In her free time, Janet enjoys spending time with her family, being active, and reading.